Table 4 Causes of death.

From: Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure

Year of transplantation

1989–2019

1989–2000

2001–2010

2011–2019

Deceased patients, n (%)

161 (73.2%)

26 (72.2%)

87 (80.6%)

48 (63.2%)

Relapse/primary disease, n (%)

93 (57.8%)

15 (57.7%)

56 (64.4%)

21 (43.8%)

Non-relapse mortality, n (%)

 Infections, n (%)

31 (19.3%)

6 (23.1%)

18 (20.7%)

11 (22.9%)

 Organ failiure/Toxicity, n (%)

11 (8.4%)

3 (11.5%)

4 (4.6%)

8 (16.7%)

 GvHD total, n (%)

18 (11.2%)

1 (3.8%)

5 (5.7%)

5 (10.4%)

 aGvHD, n (%)

8 (5%)

0 (0%)

3 (3.4%)

3 (6.3%)

 cGvHD, n (%)

10 (6.2%)

1 (3.8%)

2 (2.3%)

2 (4.2%)

 Secondary malignancy, n (%)

3 (1.9%)

1 (3.8%)

2 (2.3%)

0 (0%)

 Graft failure, n (%)

2 (1.2%)

0 (0%)

1 (1.2%)

1 (2.1%)

Unknown, n (%)

3 (1.9%)

0 (0%)

1 (1.2 %)

2 (4.2%)

  1. Shown are the causes of death in 161 patients from the entire cohort and the sub-cohorts. Causes of death include primary disease, infections, organ failure or toxicity, GvHD, graft failure, secondary malignancies and unknown causes.
  2. GvHD graft-versus-host disease, aGvHD acute graft-versus-host disease, cGvHD chronic graft-versus-host disease.
Back to article page